ARTICLE | Emerging Company Profile
Triana: Molecular glues for degradation and beyond
Launched this spring with $110M, the biotech discovers small molecule and macrocyclic molecular glues using machine learning and DEL screening
September 22, 2022 11:18 PM UTC
Triana is exploring both classical and macrocyclic small molecules as molecular glues to degrade, stabilize or change the function of cancer targets.
Launched in April with $110 million in total funding, Triana Biomedicines Inc. combines two ideas from separate seed investors, which co-led its undisclosed series A round along with Lightspeed Venture Partners; other investors include Pfizer Ventures, Citadel’s Surveyor Capital and Logos Capital. ...